Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes

Krusun, Srichai; Pesee, Montien; Supakalin, Narudom; Thamronganantasakul, Komsan; Supaadirek, Chunsri; Padoongcharoen, Prawat

doi:10.7314/apjcp.2014.15.14.5653

Cited by 14 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 Discontinuous radiation during radiochemotherapy takes place in 3-20% of the patients. [33][34][35] In the present study the interval took place in 15.7% of the patients, which is within the ranges quoted above.…”

Section: Discussion Of Resultssupporting

confidence: 90%

“…According to the literature, 70-92% of the patients receive the planned number; in the present study 5 courses of DDP were received by 65.7% of the patients, which can be crucial for the efficiency of the treatment, since receiving fewer than 5 chemotherapy courses is related with a worse prognosis for the patients. [33][34][35][36] According to the literature the age and undergone surgery do not influence the planned course of radiochemotherapy. 34,35 Similarly, in our own research the surgery and age did not influence the interval in radiotherapy, although the age influenced the number of chemotherapy courses.…”

Section: Discussion Of Resultsmentioning

confidence: 99%

“…[33][34][35][36] According to the literature the age and undergone surgery do not influence the planned course of radiochemotherapy. 34,35 Similarly, in our own research the surgery and age did not influence the interval in radiotherapy, although the age influenced the number of chemotherapy courses. According to the data from the literature and our own research, hematological complications and ones related to gastrointestinal tract are the most often reasons for the treatment course not going according to the primary plan.…”

Section: Discussion Of Resultsmentioning

confidence: 99%

“…According to the data from the literature and our own research, hematological complications and ones related to gastrointestinal tract are the most often reasons for the treatment course not going according to the primary plan. 34,35 Special attention should be paid to the hemoglobin level during radiochemotherapy. The hemoglobin level > 10 mg% before and during radiotherapy and nadir during radiotherapy is an independent prognostic and predictive factor, as it influences the longer total survivals, and the value of hemoglobin in the last 2 weeks of treatment has special meaning.…”

Section: Discussion Of Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Tolerance of combined radiochemotherapy in cervical cancer patients

Izmajłowicz¹,

Rusiecka²,

Sztuder³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Radiochemotherapy in cervical cancer was implemented to clinical practice based on 5 randomized clinical trials, published at the end of the 20 th century, which showed improvement in the total and symptomless survivals by about 10-18%. The increase of therapeutic index of such treatment can take place only when the efficiency of the treatment outweighs the increase of its toxicity. Thus, it is necessary to monitor treatment reaction during radiochemotherapy.

show abstract

Section: Discussion Of Resultssupporting

confidence: 90%

Section: Discussion Of Resultsmentioning

confidence: 99%

Section: Discussion Of Resultsmentioning

confidence: 99%

Section: Discussion Of Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Tolerance of combined radiochemotherapy in cervical cancer patients

Izmajłowicz¹,

Rusiecka²,

Sztuder³

et al. 2017

Adv Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…Interruption of treatment leads to poorer survival outcomes in uterine cervix cancer (Krusun et al, 2014). It may have an influence for better survival estimates in cancer patients with improvement of educational levels and non interruption of treatment.…”

Section: 3121 Educational Levels and Survival In Indian Patients Witmentioning

confidence: 99%

Association of Educational Levels with Survival in Indian Patients with Cancer of the Uterine Cervix

Krishnatreya¹,

Kataki²,

Sharma³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The main objective of this paper was to assess the influence of educational level on the survival of uterine cervix cancer patients in our population. A total of 224 patients were registered in our registry, of which 178 had information on stage and different educational levels. The overall median survival (MS) was 23 months, with values of 18.5, 20.7 and 41.3 months for the illiterate, literate and qualified groups, respectively. In the illiterate patients, stage I was seen in 2.6% and stage IV in 11.8%, while in other 2 groups stage I was seen in 10% to 17% of patients at the time of diagnosis. The survival probability at around 50 months was around 42%, 30% and 26% (approximately) for qualified, literates and illiterates respectively [Log Rank (Mantel-Cox) showed p=0.023]. Emphasis on imparting education to females can be a part of comprehensive cancer control programme for improving the overall survival in patients with carcinoma of the uterine cervix in our population.Keywords: Cancer cervix -educational levels -survival -Kamrup, India RESEARCH ARTICLE Association of Educational Levels with Survival in Indian Patients with Cancer of the Uterine CervixManigreeva Krishnatreya 1 *, Amal Chandra Kataki 1 , Jagannath Dev Sharma 2 , Pintu Nandy 1 , Gayatri Gogoi 1 tried to see the influence of educational level and stage at diagnosis in the survival of patients with uterine cervix cancer in our population.

show abstract

Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer

et al. 2018

View full text Add to dashboard Cite

Cervical cancer (CC) is one of the acquired immunodeficiency syndrome (AIDS) defining diseases and the human immunodeficiency virus (HIV) infection is thought to relate with increased acute toxicity of chemoradiotherapy (CRT).We investigated the effect of HIV status in the incidence of neutropenia associated with cisplatin-based CRT for CC and its impact in treatment completion.This is a single-center retrospective cohort study. Data collection was performed for all the consecutive stage Ib-IV CC women treated with cisplatin-based CRT from 2012 to 2016, and with known HIV status.Sixty-one patients were included, 6 were HIV+. HIV+ patients had a higher risk of neutropenia at any cycle during cisplatin CRT [adjusted odds ratio (OR) 7.3, 95% confidence interval (95% CI) 1.02–52.3; P = .05]. Despite the absolute differences, mean neutrophil count was nonsignificantly lower in HIV+ women, both at baseline [4455/μL (interquartile range, IQR: 1830–6689) vs 6340 (IQR: 1720–18,970) for HIV−, P = .98] and at the end of treatment [1752/μL (IQR: 1100–2930) vs 3147/μL (IQR: 920–18,390) in HIV−; P = .06]. Moreover, when considering the effect of time, CRT seems to induce a consistent drop of neutrophils in both groups (P = .229). No febrile neutropenia events occurred.In HIV+ women, there were more CT cycle delays (P = .013), patients were more prone to use granulocyte colony-stimulating factor (G-CSF; HIV+ 40.0% vs HIV− 4.0%; P = .04) and less likely to complete at least 5 cycles of cisplatin (P = .02). All patients received adequate dose of pelvic RT, regardless of HIV status.HIV+ patients have a significantly increased risk of neutropenia during CRT treatment for CC and are less likely to complete chemotherapy with cisplatin.

show abstract

Treatment Interruption During Concurrent Chemoradiotherapy of Uterine Cervical Cancer; Analysis of Factors and Outcomes

Cited by 14 publications

References 21 publications

Tolerance of combined radiochemotherapy in cervical cancer patients

Tolerance of combined radiochemotherapy in cervical cancer patients

Association of Educational Levels with Survival in Indian Patients with Cancer of the Uterine Cervix

Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer

Contact Info

Product

Resources

About